Hepatology
Norgine enters exclusive licensing agreement with Vir Biotechnology
December 18, 2025Manufacturing and Production Hepatology, Norgine, Vir Biotechnology
Norgine has announced its exclusive licensing agreement with Vir Biotechnology, under which Norgine will commercialise the combination of tobevibart and …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
September 23, 2025Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
August 22, 2025Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …
Global study calls for overhaul of hepatitis B care to meet WHO targets
August 21, 2025Medical Communications, Medical/ Scientific Writing Hepatology, World Health Organisation, hepatitis B, liver damage, medical study
A major global study has warned that current models of hepatitis B care are failing patients and could jeopardise the …
Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development
June 30, 2025Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics
Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …
FDA approves drug for primary biliary cholangitis
August 15, 2024Research and Development FDA Approval, FDA approva;, Hepatology, liver, primary biliary cholangitis
Accelerated approval has been granted for Gilead Science’s Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) by the US Food …
Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial
July 26, 2024Research and Development Calliditas, Hepatology, clinical trials, elevated liver stiffness, primary biliary cholangitis
Calliditas Therapeutics AB today announced that the phase 2b TRANSFORM trial met its primary endpoint. The trial showed statistically significant …
First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment
June 19, 2024Research and Development Assembly Biosciences, Hepatology, clinical trial, hepatitis
Assembly Biosciences has announced that the first participant has been dosed in its phase 1b trial of ABI-4334, the company’s …
Eli Lilly shares results for tirzepatide for MASH resolution
June 10, 2024Research and Development Eli Lilly, Hepatology, MASH, clinical trial, liver
Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, with or without type 2 …
Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis
June 5, 2024Research and Development Gilead, Hepatology, clinical trials, primary biliary cholangitis, seladelpar
Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …
Mirum Pharmaceuticals publishes phase 3 MARCH maralixibat data in The Lancet
May 8, 2024Research and Development Hepatology, Mirum Pharmaceuticals, PFIC, The Lancet, clinical trials
Biopharma company Mirum Pharmaceuticals has announced data from its phase 3 MARCH-PFIC study which evaluated maralixibat in patients with progressive …
Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment
February 26, 2024Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide
Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …
GSK gains FDA Fast Track designation for chronic hepatitis B treatment
February 12, 2024Medical Communications FDA, GSK, Hepatology, fast track designation, hepatitis B
GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational …
Bit.bio announces cell therapy pipeline
November 8, 2023Medical Communications Hepatology, bit.bio, cell therapy, liver failure
Bit.bio has announced its cell therapy pipeline as well as having shared its lead cell therapy candidate, preparing to enter …
Inventiva and Echosens collaborate to bring awareness to NASH and encourage screening for at-risk patients
June 8, 2023Medical Education Echosens, Hepatology, Inventiva, liver disease, nash, non-alcoholic steatohepatitis
French clinical stage biopharmaceutical company Inventiva has announced a collaboration with US-based high-technology company Echosens to bring attention to, and …
